Status:
COMPLETED
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
Lead Sponsor:
Solvay Pharmaceuticals
Conditions:
Early Stage Parkinson's Disease
Eligibility:
All Genders
30+ years
Phase:
PHASE3
Brief Summary
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
Eligibility Criteria
Inclusion
- Patients who have completed S308.3.003 trial
Exclusion
- Patients with medically relevant abnormal findings (ECG, physical examination, AEs) at end of the maintenance phase (visit M6, week 24) of study S308.3.003
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT00335374
Start Date
August 1 2007
End Date
November 1 2008
Last Update
February 6 2009
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
419
Birmingham, Alabama, United States
2
413
Oceanside, California, United States
3
408
Oxnard, California, United States
4
422
New Haven, Connecticut, United States